Captopril
Captopril (captopril) is a small molecule pharmaceutical. Captopril was first approved as Capoten on 1982-01-01. It is used to treat bartter syndrome, diabetic nephropathies, edema, heart failure, and left ventricular dysfunction amongst others in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Captopril
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAPOTEN | Strides Pharma Global | N-018343 DISCN | 1982-01-01 | 7 products, RLD |
Hide discontinued
Captopril
+
Hydrochlorothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAPOZIDE 25/15 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
| CAPOZIDE 25/25 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
| CAPOZIDE 50/25 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
| CAPOZIDE 50/15 | Bristol Myers Squibb | N-018709 DISCN | 1984-10-12 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| captopril | ANDA | 2024-01-11 |
| captopril and hydrochlorothiazide | ANDA | 2023-02-21 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
86 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | — | 1 | 6 | 5 | 15 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | 1 | 5 | 6 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 1 | 1 | 1 | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | 2 | 2 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 3 | — | 4 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 1 | — | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | 1 | — | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 1 | 1 | 2 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | 1 | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | 1 | — | — | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 2 | — | — | 2 |
| Essential hypertension | D000075222 | — | I10 | 1 | 1 | 1 | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | 1 | — | — | 2 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | — | 1 | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood pressure | D001794 | EFO_0004325 | — | 1 | 1 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | 1 | — | — | — | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
| Radiation pneumonitis | D017564 | EFO_1001411 | J70.0 | — | 1 | — | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | 1 | — | — | — | 1 |
| Individuation | D007207 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Multiple system atrophy | D019578 | — | — | 1 | — | — | — | — | 1 |
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | 1 | — | — | — | — | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
| Aneurysm | D000783 | HP_0002617 | I72.9 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 1 | 1 |
| Peri-implantitis | D057873 | EFO_1001390 | — | — | — | — | — | 1 | 1 |
| Heart murmurs | D006337 | HP_0030148 | R01.0 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Captopril |
| INN | captopril |
| Description | Captopril is a L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is a pyrrolidinemonocarboxylic acid, a N-acylpyrrolidine, an alkanethiol and a L-proline derivative. |
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; antihypertensives (ACE inhibitors) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 62571-86-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1560 |
| ChEBI ID | 3380 |
| PubChem CID | 44093 |
| DrugBank | DB01197 |
| UNII ID | 9G64RSX1XD (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Captopril
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Captopril
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,741 documents
View more details
Safety
Black-box Warning
Black-box warning for: Captopril, Captopril and hydrochlorothiazide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,440 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use